(0.25%) 5 144.25 points
(0.20%) 38 519 points
(0.34%) 17 907 points
(-0.56%) $83.38
(1.98%) $1.961
(0.04%) $2 348.20
(0.32%) $27.62
(0.88%) $930.25
(-0.20%) $0.933
(-0.31%) $10.99
(-0.34%) $0.798
(1.14%) $92.93
Live Chart Being Loaded With Signals
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies...
Stats | |
---|---|
本日の出来高 | 202 694 |
平均出来高 | 362 538 |
時価総額 | 201.95M |
EPS | $0 ( 2024-04-01 ) |
次の収益日 | ( $-0.420 ) 2024-05-20 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.75 |
ATR14 | $0.0240 (0.35%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-28 | Nicholson, C. David | Buy | 70 311 | Stock Option (Right to Buy) |
2023-12-28 | Steinhart Richard I | Buy | 70 311 | Stock Option (Right to Buy) |
2023-12-28 | O'loughlin Steve | Buy | 253 123 | Stock Option (Right to Buy) |
2023-12-28 | Shetty Ajit | Buy | 70 311 | Stock Option (Right to Buy) |
2023-12-28 | Seth Sandesh | Buy | 984 367 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
100.00 |
Last 100 transactions |
Buy: 13 159 883 | Sell: 1 707 212 |
ボリューム 相関
Actinium Pharmaceuticals 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Actinium Pharmaceuticals 相関 - 通貨/商品
Actinium Pharmaceuticals 財務諸表
Annual | 2023 |
収益: | $81 000.00 |
総利益: | $-709 000 (-875.31 %) |
EPS: | $-1.830 |
FY | 2023 |
収益: | $81 000.00 |
総利益: | $-709 000 (-875.31 %) |
EPS: | $-1.830 |
FY | 2022 |
収益: | $1.03M |
総利益: | $331 000 (32.14 %) |
EPS: | $-1.320 |
FY | 2021 |
収益: | $1.14M |
総利益: | $1.14M (100.00 %) |
EPS: | $-2.17 |
Financial Reports:
No articles found.
Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。